Evidence map›Paper›PMID 9234763›Full record

ArticleInfection and immunity1997

Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice.

E T Ryan, J R Butterton, T Zhang, M A Baker, S L Stanley, S B Calderwood

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 61 citations in OpenAlex.

  1. A Strategy for the Rapid Development of a SafeInternational journal of molecular sciences · 2021
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Cholera toxin: a paradigm of a multifunctional protein.The Indian journal of medical research · 2011
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

E T RyanInfectious Disease Unit, Massachusetts General Hospital, Boston 02114, USA.
J R Butterton
T Zhang
M A Baker
S L Stanley
S B Calderwood
Massachusetts General Hospital · US

Funding

MOLECULAR DISSECTION OF E. HISTOLYTICA PATHOGENESISR01AI030084 · NIAID · WASHINGTON UNIVERSITY · PI STENSON, WILLIAM F. · 1992 to 2010
$3.3M
Mucosal Immunity to Antigens Expressed by V.choleraeR01AI040725 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RYAN, EDWARD T. · 1997 to 2006
$2.5M
CHOLERA-VECTORED DELIVERY SYSTEM FOR PERTUSSIS ANTIGENSK08AI001386 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BUTTERTON, JOAN R · 1996 to 1998
–
NIAID NIH HHS AI30084NIAID NIH HHS AI40725NIAID NIH HHS KO8 AI01386NIAID NIH HHS R01 AI030084NIAID NIH HHS R01 AI040725
6 · The paper itself

Abstract

Entamoeba histolytica is a significant cause of morbidity and mortality worldwide. The serine-rich E. histolytica protein (SREHP) is a surface-expressed trophozoite protein that includes multiple hydrophilic tandem repeats. A purified fusion protein between the dodecapeptide repeat of SREHP and cholera toxin B subunit (CTB) has previously been shown to be immunogenic in mice after oral inoculation when cholera toxin is coadministered as an immunoadjuvant. We engineered a live attenuated El Tor Vibrio cholerae vaccine strain, Peru2, to express the SREHP-12-CTB fusion protein to the supernatant from either a plasmid [Peru2 (pETR5.1)] or from a chromosomal insertion (ETR3). Vector strains were administered orally to germfree mice that were subsequently housed under nongermfree conditions; mice received one (day 0) or two (days 0 and 14) inoculations. No immunoadjuvant or cholera holotoxin was administered. Mice that received two inoculations of Peru2(pETR5.1) had the most pronounced antiamebic systemic and mucosal immunologic responses. Less marked, but significant, anti-SREHP serum immunoglobulin G antibody responses were also induced in mice that received either one or two oral inoculations of strain ETR3. Anti-V. cholerae responses were also induced, as measured by the induction of serum vibriocidal antibodies and by serum and mucosal anti-CTB antibody responses. These results suggest that V. cholerae vector strains can be successful delivery vehicles for the SREHP-12-CTB fusion protein, to induce mucosal and systemic antiamebic and anti-V. cholerae immune responses. The magnitude of these responses is proportional to the amount of SREHP-12-CTB produced by the vector strain.

Indexed as

Administration, OralAnimalsAntibodies, BacterialAntibodies, ProtozoanCholera ToxinEntamoeba histolyticaFemaleImmunizationIntestinesMiceProtozoan ProteinsProtozoan VaccinesRecombinant Fusion ProteinsVaccines, AttenuatedVaccines, SyntheticVibrio choleraeAntibodies, BacterialAntibodies, ProtozoanCholera ToxinProtozoan ProteinsProtozoan VaccinesRecombinant Fusion ProteinsVaccines, AttenuatedVaccines, Synthetic

Identifiers

PMID9234763
PMCPMC175440
OpenAlexW2143350546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.